55 a share from its prior view of at least $6.

35 to $6 More information here .55 a share from its prior view of at least $6.25 a share. The insurer in February stated it expects to lose money on its business in the Affordable Care Take action marketplaces this year, with the demographics of enrollees skewing slightly more than expected toward people likely to rack up higher costs. Still, the business noted that individual insurance represents a little part of operating income . An interview with Dr Chhatwal NPR: Expensive Hepatitis C Tablet Shreds Drug Industry Sales Record The start of Sovaldi, the $1,000-a-day tablet for hepatitis C, is shaping up as the most successful ever. In December The Food and Medication Administration approved the pill. And Gilead Sciences was off to the races then.